63190-57-8

Upstream product

• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 108-24-7 acetic anhydride 

Downstream Products

• 35241-23-7 6,7-dimethoxy-2-methylquinazolin-4-ol 
• 50377-49-6 4-chloro-6,7-dimethoxy-2-methylquinazoline 
• 849218-00-4 N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide 
• 849218-01-5 6,7-dimethoxy-2-methyl-4-(4-nitro-phenoxy)-quinazoline 
• 849218-02-6 4-(6,7-dimethoxy-2-methyl-quinazolin-4-yloxy)-phenylamine 

Relevant academic research and scientific papers

Quinazolin-4-one derivatives

A medicament having an inhibitory activity against hematopoietic prostaglandin D2 synthase, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein X represents a group represented by the formula —N═C(R5)— or the formula —NH—CH(R5)—, R1, R2, R3, and R4 represent a hydrogen atom, a halogen atom, a C1 to C6 alkyl group, or a hydroxy group, R5 represents a C1 to C6 alkyl group or a C6 to C10 aryl group, and R represents an amino group.

C-MET MODULATORS AND METHODS OF USE

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.